PFE · 10-Q · 2026Q3 · Full report

Trade Policy and Tariffs

PFIZER INC · 2026-11-03 · Importance 53 · Surprise 60

On April 2, 2026, the U.S. Government announced Section 232 tariffs of up to 100% on imported patented pharmaceuticals and their ingredients, citing national-security concerns about supply-chain reliance. The measures, which include exemptions tied to U.S. manufacturing commitments, became effective for Pfizer on July 31, 2026. Under final binding agreements with the U.S. Government, Pfizer’s applicable tariff rate under the order will be zero until January 20, 2029. Pfizer also committed to measures intended to make certain U.S. drug prices more comparable with those in other developed countries, offer certain medicines at significant discounts to current retail prices, and further invest in U.S. manufacturing.

Key facts

• Under binding agreements with the U.S. Government, Pfizer committed to make certain U.S. drug prices more comparable with other developed countries, offer certain medicines at significant discounts to current retail prices, and further invest in U.S. manufacturing. source
• The U.S. announced Section 232 tariffs of up to 100% on imported patented pharmaceuticals and their ingredients on April 2, 2026; the measures became effective for Pfizer on July 31, 2026. source
• The applicable Section 232 tariff rate for Pfizer products will be zero until January 20, 2029, under Pfizer's agreements with the U.S. Government. source